NIA: Alzheimer's Biomarker Tests Suited for Research, Not Clinic | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic biomarker-based tests designed to predict individual risk for Alzheimer's disease may be valuable in research projects and potential treatments, but they are not ready to provide valuable information for use in predicting disease risk in the clinic, according to a new set of Alzheimer's diagnostic guidelines issued Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.